severe obesity
Endocrinology · 2006–2022
5decisions
2medicines
1carried consumer input
27individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| semaglutide Treatment of severe obesity (BMI ≥35 kg/m² with at least one weight-related comorbidity, excluding patients with type 2 diabetes) as an adjunct to a… | Mar 2022 | Not recommended | 27 individuals Diabetes Australia · Weight Issues Network |
| sibutramine hydrochloride For the treatment of severe obesity (BMI ≥ 35 kg/m2) with two or more of the following risk factors: Type 2 diabetes, adequately controlled hypertension (<… | Mar 2006 | Not recommended | no section in document |
| sibutramine hydrochloride Treatment of severe obesity (BMI ≥ 35 kg/m²) in the presence of two or more risk factors including Type 2 diabetes, hypertension, high triglycerides, or low… | Mar 2006 | Not recommended | no section in document |
| sibutramine hydrochloride For the treatment, in conjunction with a reduced caloric diet, of severe obesity (BMI > 35 kg/m2) in adults between 18 and 65 years of age who meet specific… | Nov 2006 | Not recommended | no section in document |
| sibutramine hydrochloride Management of severe obesity (BMI > 35 kg/m²) in adults aged 18–65 years with inadequate response to diet and/or exercise, in conjunction with a… | Nov 2006 | Not recommended | no section in document |
Who spoke
Diabetes Australia · Weight Issues Network
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.